Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company specializing in molecular glue degrader (MGD)-based medicines, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Markus Warmuth, M.D., will deliver a presentation on Tuesday, January 14, 2025, at 5:15 p.m. PST.
The presentation will be accessible through a webcast via the 'Events & Presentations' section of Monte Rosa's investor relations website at ir.monterosatx.com. An archived version of the presentation will remain available for 30 days following the event.
Monte Rosa Therapeutics (Nasdaq: GLUE), un'azienda biotecnologica in fase clinica specializzata in medicinali a base di degradatori di molecole adesive (MGD), ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. Il CEO dell'azienda, Markus Warmuth, M.D., terrà una presentazione martedì 14 gennaio 2025, alle 17:15 PST.
La presentazione sarà accessibile tramite webcast nella sezione 'Eventi e Presentazioni' del sito dedicato alle relazioni con gli investitori di Monte Rosa all'indirizzo ir.monterosatx.com. Una versione archiviata della presentazione rimarrà disponibile per 30 giorni dopo l'evento.
Monte Rosa Therapeutics (Nasdaq: GLUE), una empresa de biotecnología en etapa clínica especializada en medicamentos basados en degradadores de pegamento molecular (MGD), ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. El CEO de la empresa, Markus Warmuth, M.D., realizará una presentación el martes 14 de enero de 2025, a las 5:15 p.m. PST.
La presentación será accesible a través de un webcast en la sección 'Eventos y Presentaciones' del sitio web de relaciones con inversores de Monte Rosa en ir.monterosatx.com. Una versión archivada de la presentación estará disponible durante 30 días después del evento.
몬테 로사 테라퓨틱스 (Nasdaq: GLUE)는 분자 접착제 분해제(MGD) 기반 의약품에 특화된 임상 단계 생명공학 회사로, 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 마르쿠스 바무스(M.D.)는 2025년 1월 14일 화요일 오후 5시 15분 PST에 프레젠테이션을 진행할 예정입니다.
프레젠테이션은 몬테 로사의 투자자 관계 웹사이트의 '이벤트 및 프레젠테이션' 섹션을 통해 웹캐스트를 통해 시청할 수 있습니다. 프레젠테이션의 아카이브 버전은 이벤트 후 30일 동안 이용 가능합니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une entreprise de biotechnologie en phase clinique spécialisée dans les médicaments basés sur des dégradateurs de colle moléculaire (MGD), a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan sur la Santé. Le PDG de l'entreprise, Markus Warmuth, M.D., fera une présentation le mardi 14 janvier 2025, à 17h15 PST.
La présentation sera accessible via un webinaire dans la section 'Événements et Présentations' du site Web des relations investisseurs de Monte Rosa à ir.monterosatx.com. Une version archivée de la présentation restera disponible pendant 30 jours après l'événement.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf molekulare Kleberzerstörer (MGD)-basierte Medikamente spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference angekündigt. Der CEO des Unternehmens, Markus Warmuth, M.D., wird am Dienstag, den 14. Januar 2025, um 17:15 Uhr PST eine Präsentation halten.
Die Präsentation wird über einen Webcast in der Rubrik 'Veranstaltungen und Präsentationen' auf der Investor Relations-Website von Monte Rosa unter ir.monterosatx.com zugänglich sein. Eine archivierte Version der Präsentation bleibt für 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will Monte Rosa's (GLUE) J.P. Morgan Conference presentation be available online?
Where can investors access Monte Rosa's (GLUE) J.P. Morgan Healthcare Conference presentation?
What type of medicines does Monte Rosa Therapeutics (GLUE) develop?
